Overview

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Status:
RECRUITING

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Phase:

PHASE3

Details

Lead Sponsor:

Viridian Therapeutics, Inc.